Cadrenal Therapeutics, Inc. (CVKD) Misses Q2 EPS by 61c

Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) reported Q2 EPS of ($1.87), $0.61 worse than the analyst estimate of ($1.26). Revenue for the quarter came in at $0 , versus $0 reported last year.

For earnings history and earnings-related data on Cadrenal Therapeutics, Inc. (CVKD) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Morgan Stanley Upgrades Galp Energia SGPS SA (GALP:LI) (GLPEF) to Overweight
• Danone SA (BN:FP) (DANOY) PT Raised to EUR63 at Deutsche Bank